liver disease face, the head, face, trunk and limbs were widely distributed with miliary to soybean size red pimples, it was more obvious on the trunk, with partially confluent lesions, a clear border around the visible flush, rough surface, covered with the silverwhite dander, petechial hemorrhage was visible when the dander was scraped.
Treatment and prognosis
After the diagnosis of chronic hepatitis B cirrhosis (decompensation), treatment of orthotopic piggyback liver transplantation in general anesthesia was given on June 26, 2009, the surgery went well. Three mg FK506 was orally taken per day for the prevention of immune rejection from June 28, 2009. During postoperative recovery period, systemic rash gradually subsided, leaving only a small amount of pigmentation. The skin itch was basically eased and was disappeared completely on July18, 2009. The patient was discharged from hospital. Up to now, there's no recurrence. The treatment was listed in Table 1 .
DISCUSSION
As a dermatopathic common disease with a prevalence rate of about 1% to 3%, 1 psoriasis is characterized by CD4 + T lymphocyte-mediated autoimmune disorder, 2 inflammatory cell infiltration and keratinocyte hyperplasia.
3 At present, the main treatment for psoriasis is systemic medication, such as taking retinoid drugs or immunosuppressive agents, which has an exact effect but the side effects are Psoriasis is a chronic recurrent inflammatory dermatosis, which is characterized by epidermal proliferation and erythema scales. Its etiology and pathogenesis are still unknown and treatment is difficult. The concentration of tacrolimus for the treatment of psoriasis has not been reported at home and abroad. In this report, we detected the tacrolimus plasma concentration and hope to provide a certain reference value for the clinical treatment of psoriasis. 5 The action mechanism of FK506 -FKBP-complex (FK506 combining with FK506 binding protein in the T lymphocytes cytoplasm) in vivo are inhibition of phosphorylase phosphatase activity of calmodulin, the anti-host reaction and delayed hypersensitivity.
5 Mrowietz et al in 1996 firstly reported a double-blind, placebo-controlled, multi-center clinical trials that 50 cases of severe refractory plaque psoriasis patients who were given oral administration of tacrolimus 0.05 mg/kg per day, compared with placebo group, there was no significant difference on the lesions area improvement after three weeks, then the dose of Tacrolimus was increased to 0.1 mg/kg per day, clinical symptoms improved three weeks later. Then the tacrolimus dose was increased to 0.15 mg/kg per day until the nine weeks comprehensive treatment. 6 It has shown that the regional lesions was decreased by 83% in treatment group and by 47% in the placebo group, tacrolimus is an effective method for treatment of refractory severe psoriasis, which was well tolerated and has minor side effects. Its adverse reactions were diarrhea, abdominal pain, nausea, paresthesia, tremor, elevated blood pressure, heart palpitations, it also has some impacts on the function of kidney and liver. The side effects of FK506 is closely related to plasma concentration, its treatment concentration was 5-20 ng/ml, thus it's necessary to strengthen the monitoring of plasma concentration and formulate a reasonable individual and secure treatment scheme.
7
The reports of 0.1% and 0.03% tacrolimus ointment treatment for psoriasis can be retrieved, but oral FK506 systemic treatment of psoriasis has not been reported at home. Mrowietz et al reported the dose and duration of FK506 treatment for refractory psoriasis, but exact plasma concentration of FK506 in the treatment of psoriasis has not been reported. +++ skin rashes with skin itching. ++ skin rashes without skin itching. + little skin rashes and no itchy skin. Space stands for no detection.
Table1. The treatment and efficacy

